IGNYTA INC / ROCHE HOLDING AG / Tender Offer / Acquisition / Public / £1447m

Financials

Transaction Value-

Consideration TypeCash

Capital Owned-

Capital Bid For-

EV/Sales-

EV/EBITDA-

Share Price Premium-

One Off Charge-

Ignyta

Roche Holdings

Sources

Tags

treatment development

biotechnology

Biotechnology

United States

Public

Acquisition

Tender Offer

Pending

Friendly

Single Bidder

Synopsis

Sale of Ignyta, a precision oncology biotechnology company, to Roche Holdings.

Bank Of America

Jp Morgan

Latham & Watkins

Citigroup

Sidley Austin

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.